Everolimus (Certican, Afinitor, Zortress, SDZ-RAD, RAD001, 40-O-(2-hydroxyethyl)-rapamycin), >99%

LC Laboratories' Product Number E-4040 - Everolimus (Certican, Afinitor, Zortress, SDZ-RAD, RAD001, 40-O-(2-hydroxyethyl)-rapamycin), >99% - for research use only. Everolimus is an immunosuppressant analog of rapamycin (sirolimus) and inhibits growth factor-mediated proliferation of haematopoietic and nonhaematopoietic cells. Everolimus shows a potent inhibitory effect on posttransplant lymphoproliferative disorder (PTLD)-derived cells in vitro and in vivo, in a dose range that can prevent allograft rejection, and may demonstrate activity in both the prevention and treatment of PTLDs in transplant patients. Oral everolimus inhibits in-stent neointimal growth in the rabbit iliac artery. Everolimus was well tolerated at a dose of 1.5 mg/kg given 1 day before stenting followed by 0.75 mg/kg per day for 28 days and was related with significant neointimal healing. Everolimus is the active ingredient in the drug sold under the tradename Certican and in the drug-eluting stent sold under the tradename XienceV. The drug has been approved in at least one country for the prophylaxis of organ rejection in patients who have received a kidney or heart transplant, and the stent is approved for use in patients undergoing angioplasty.

• Supplier: LC Laboratories
• Product #: E-4040
• Sku #: E-4040_250mg